246 related articles for article (PubMed ID: 11248095)
1. Preselective gene therapy for Fabry disease.
Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
[TBL] [Abstract][Full Text] [Related]
2. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
3. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
[TBL] [Abstract][Full Text] [Related]
4. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
8. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
[TBL] [Abstract][Full Text] [Related]
10. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
11. Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease.
Yokoi T; Kobayashi H; Shimada Y; Eto Y; Ishige N; Kitagawa T; Otsu M; Nakauchi H; Ida H; Ohashi T
J Gene Med; 2011 May; 13(5):262-8. PubMed ID: 21520359
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
[TBL] [Abstract][Full Text] [Related]
13. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.
Takenaka T; Qin G; Brady RO; Medin JA
Hum Gene Ther; 1999 Aug; 10(12):1931-9. PubMed ID: 10466627
[TBL] [Abstract][Full Text] [Related]
14. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
15. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
Lee CJ; Fan X; Guo X; Medin JA
J Cardiol; 2011 Jan; 57(1):115-22. PubMed ID: 20846825
[TBL] [Abstract][Full Text] [Related]
16. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
Germain DP
J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
[TBL] [Abstract][Full Text] [Related]
17. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity.
Ramsubir S; Yoshimitsu M; Medin JA
Mol Ther; 2007 Jun; 15(6):1174-81. PubMed ID: 17387334
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 (IL-12) gene therapy of leukemia: immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells.
Gautam SC; Xu YX; Dumaguin M; Janakiraman N; Chapman RA
Cancer Gene Ther; 2000 Jul; 7(7):1060-8. PubMed ID: 10917209
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of TGF-beta activity during retroviral transduction improves murine hematopoietic progenitor and repopulating cell gene transfer efficiency.
Yu J; Soma T; Hanazono Y; Dunbar CE
Gene Ther; 1998 Sep; 5(9):1265-71. PubMed ID: 9930329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
